Meeting Minutes

Date: Wednesday, September 17, 2014
Time: 10:00 AM – 12:00 PM
Location: Health Sciences Building T-269

Members Present:
1. Thea Brabb, Comparative Medicine
2. H.D. “Toby” Bradshaw, Biology
3. Lesley Colby, Comparative Medicine
4. Elizabeth Corwin, Community Member
5. Jean Haulman, UW Travel Clinic
6. Stephen Libby, Laboratory Medicine
7. Scott Meschke, Environmental & Occupational Health Sciences
8. Jeanot Muster, Pharmacology
9. Eric Stefansson, Environmental Health & Safety
10. Paul Swenson, Community Member, Seattle-King Co. Dept of Public Health

Members Absent:
11. Michael Agy, Washington National Primate Research Center
12. Matthew R. Parsek, Associate Professor, Microbiology
13. Mei Y. Speer, Bioengineering
14. Valerie Yerkes, Community Member

Guests Present:
1. Linda Arnesen, Biosafety Officer, EH&S Research & Occupational Safety
2. Andrea Badger, IBC/Research Coordinator, EH&S Research & Occupational Safety
3. Jacqui Bales, Biosafety Officer, EH&S Research & Occupational Safety
4. Tony Han, Biosafety Officer, EH&S Research & Occupational Safety
5. Katia Harb, Assistant Director, EH&S Research & Occupational Safety
6. Laury Istvan, Assistant Director, Office of Animal Welfare
7. Lesley Leggett, Biosafety Officer, EH&S Research & Occupational Safety
8. Glenn McLean, Biosafety Officer, EH&S Research & Occupational Safety
1. **CALL TO ORDER:** Steve Libby called the meeting to order at 10:05. A quorum was present.

2. **REMINDER:** Steve Libby reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **APPROVAL OF MINUTES:**
   - Steve Libby sought a motion to approve the minutes from the August 20, 2014 minutes meeting.
   - Jean Haulman made a motion to approve the August 20, 2014 minutes. Eric Stefansson seconded the motion.
   - The committee voted unanimously to approve the August 20, 2014 meeting minutes.

4. **BIOSAFETY OFFICER (BSO) REPORTS:** The BSO reports are for project reviews involving infectious agents and for projects falling under Section III-E and III-F of the *NIH Guidelines*.
   a. Biosafety Officer Report
      - Dr. Doty’s plant research project was reviewed by the plant expert on the committee.
      - Steve Libby sought a motion to approve this month’s Biosafety Officer Report.
      - Eric Stefansson’s made a motion to approve this month’s Biosafety Officer Report. Scott Meschke seconded the motion.
      - The Committee voted unanimously, with one abstention, to approve this month’s Biosafety Officer Report.

5. **CATEGORY III-D AMENDMENTS**
   1. Reh, Thomas, change, *Photoreceptor Survival Factors in Mouse Cell Cultures*
      - Lesley Leggett served as the Biosafety Officer Reviewer. Steve Libby endorsed the review.
      - This change requests the use of AAV (adeno-associated viral vectors) and lentiviral vectors in rats. The Reh lab is already approved to work with AAV and lentiviral vectors in mice.
      - Training has been completed.
      - The draft BUA letter was shown.
      - Steve Libby made a motion to approve the draft BUA for Dr. Reh. A second is not needed since he endorsed the review.
      - The Committee voted unanimously to approve the draft BUA for Dr. Reh.

   2. Rubel, Edwin, change, *Development, Function, and Regeneration of the Auditory System + in Ovo Gene Expression; Fluorescent labeling of neurons using sindbis virus in vitro*
      - Linda Arnesen served as the Biosafety Officer Reviewer. Steve Libby endorsed the review.
      - This change requests the use of AAV in chicken embryos and chickens. The IBC has already approved AAV in mice at a previous meeting.
      - The PI’s biosafety training is expired.
      - The BUA application is still unsigned.
      - The draft BUA letter was shown.
      - Steve Libby made a motion to approve the draft BUA for Dr. Rubel. A second is not needed since he endorsed the review.
• The Committee voted unanimously to approve the draft BUA for Dr. Rubel, pending completion of training and signing the BUA application.

3. West, Timothy Eoin, change, Host genetics and response to infection
• Jacqui Bales served as the Biosafety Officer Reviewer. Steve Libby endorsed the review.
• This change requests the addition of new strains of B. pseudomallei and B. thailandensis. The investigator is already approved for other strains of these agents.
• The draft BUA letter was shown.
• The NIH section for B. thailandensis says III-D on the BUA letter, but because B. thailandensis is a risk group 1 agent, the correct section should be III-E.
• Steve Libby made a motion to approve the draft BUA for Dr. West. A second is not needed since he endorsed the review.
• The Committee voted unanimously to approve the draft BUA for Dr. West, contingent upon correcting the BUA letter to state the correct NIH guidelines section.

6. INDIVIDUAL PROJECT REVIEWS

4. Campbell, Lee Ann, renewal, Chlamydia pneumoniae antigens of biological significance
• Jean Haulman served as the Primary Reviewer and Glenn McLean served as the Biosafety Officer Reviewer. Jean Haulman presented the Primary Reviewer Report.
• The investigator studies Chlamydia and uses several strains of Chlamydia both in-vitro and in-vivo.
• C. trachomatis and C. pneumoniae are both human pathogens, but treatments are available. Medical follow-up procedures for accidental exposure are in place.
• The lab inspection has been completed and the PI has completed training.
• A discussion of the use of III-D* occurred. The III-D* notation on the BUA letter is used to represent the use of wild-type Chlamydia strains in transgenic mice.
• The draft BUA letter was shown.
• Jean Haulman made a motion to approve the draft BUA for Dr. Campbell. A second is not needed since she is the Primary Reviewer.
• The Committee voted unanimously to approve the draft BUA for Dr. Campbell.

5. Hotchkiss, Charlotte, renewal, WaNPRC Colonies
• Thea Brabb served as the Primary Reviewer and Glenn McLean served as the Biosafety Officer Reviewer. Thea Brabb presented the Primary Reviewer Report.
• This is a holding protocol for the primate center. In the unlikely event that an investigator’s protocol expires, any primates are transferred to this protocol so that they can continue to receive standard veterinary care. No research is conducted as a part of this protocol.
• Dr. Hotchkiss needs a BUA because animals that have been inoculated with ABSL-2, ABSL 2-with-3 practices, or ABSL-3 agents may be transferred to this protocol.
• The draft BUA letter was shown.
• Thea Brabb made a motion to approve the draft BUA for Dr. Hotchkiss. A second is not needed since she is the Primary Reviewer.
• The Committee voted unanimously to approve the draft BUA for Dr. Hotchkiss.
6. Kiem, Hans-Peter, renewal, Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection
   - Scott Meschke served as the Primary Reviewer and Lesley Leggett served as the Biosafety Officer Reviewer. Scott Meschke presented the Primary Reviewer Report.
   - The Kiem lab studies gene therapy as a potential way of treating HIV/AIDS.
   - Agents used on this protocol include a variety of viral vectors (AAV, lentiviral vectors, foamyviral vectors, etc.), SHIV, and also non-human primate blood and tissues.
   - Dr. Kiem is a FHCRC researcher and the in-vitro work will be done at his lab at FHCRC. Most of the animal work will be conducted here at UW.
   - The investigator should check III-F and BSL-2 on the BUA application.
     - Post-Meeting Update: We decided that these updates were not necessary, because the III-F and BSL-2 work will not be done at UW, only FHCRC.
   - The IACUC protocol needs to be revised to appropriately list all viral vector work.
   - The draft BUA letter was shown.
   - Scott Meschke made a motion to approve the draft BUA for Dr. Kiem. A second is not needed since he is the Primary Reviewer.
   - The Committee voted unanimously to approve the draft BUA for Dr. Kiem, pending correction of the BUA application and IACUC protocol.

7. Mahoney, William, renewal, Developmental and pathological properties of the cardiovascular system
   - Lesley Colby served as the Primary Reviewer and Glenn McLean served as the Biosafety Officer Reviewer. Lesley Colby presented the Primary Reviewer Report.
   - The lab studies vascular development and restoration in response to injury.
   - The agents used in this protocol include human cells and viral vectors.
   - The BUA includes gammaretroviral vector injection of mice and rats, but this is not mentioned on the IACUC protocol. The PI needs to clarify this work.
   - The PI also needs to clarify which cell sorting facility will be used.
   - The draft BUA letter was shown.
   - Lesley Colby made a motion to approve the draft BUA for Dr. Mahoney. A second is not needed since she is the Primary Reviewer.
   - The Committee voted unanimously to approve the draft BUA for Dr. Mahoney, contingent upon clarification of the gammaretroviral vectors and cell sorting facility.

8. Osborne, William, change, Gene therapy vectors
   - Steve Libby served as the Primary Reviewer and Glenn McLean served as the Biosafety Officer Reviewer. Steve Libby presented the Primary Reviewer Report.
   - This is a change requesting to add the use of adenoviral vectors.
   - The training and the lab inspection both have been completed.
   - The draft BUA letter was shown.
   - Steve Libby made a motion to approve the draft BUA for Dr. Osborne. A second is not needed since he is the Primary Reviewer.
   - The Committee voted unanimously to approve the draft BUA for Dr. Osborne.

9. Steiner, Robert, renewal, Neuropeptide Genes Governing Reproduction
• Elizabeth Corwin served as the Primary Reviewer and Linda Arnesen served as the Biosafety Officer Reviewer. Elizabeth Corwin presented the Primary Reviewer Report.
• The lab studies how specific neurons are involved in thermoregulation. The overall goal of the lab is to develop mouse models that can be used to study and develop therapies for hot flashes.
• Adeno-associated viral vectors are used in this research.
• The investigator checked both “yes” and “no” to the question about biotoxin use. Linda Arnesen called the PI and confirmed that they are not using biotoxins.
• The lab inspection and training have been completed.
• The draft BUA letter was shown.
• Elizabeth Corwin made a motion to approve the draft BUA for Dr. Steiner. A second is not needed since she is the Primary Reviewer.
• The Committee voted unanimously to approve the draft BUA for Dr. Steiner, contingent upon correction of question 94 (about biotoxins).

10. Stempien-Otero, April, change, *Macrophages in Cardiac Fibrosis*
• Paul Swenson served as the Primary Reviewer and Linda Arnesen served as the Biosafety Officer Reviewer. Paul Swenson presented the Primary Reviewer Report.
• This is a change requesting to add injection of recombinant bone marrow from transgenic mice into wild-type or other transgenic mice.
• A discussion was raised regarding whether or not this truly falls under section III-D of the NIH Guidelines.
• The research is actually exempt under the transgenic rodents exemption of the NIH Guidelines (Appendix C-VII and C-VIII).
• Therefore, the committee will not vote on this project and Dr. Stempien-Otero will not be issued a BUA letter for this work. She will instead receive a notice that her project has been registered with the IBC.

11. Zalatan, Jesse, new, *Physical organizing principles of biological signaling protein networks*
• Jeanot Muster served as the Primary Reviewer and Jacqui Bales served as the Biosafety Officer Reviewer. Jeanot Muster presented the Primary Reviewer Report.
• This is a new project. The investigator studies the molecular mechanisms of cell signaling.
• Agents to be used for this project include human source material, lentiviral vectors, and baculovirus,
• The lab is still getting set up, so not all equipment is in place yet. However, before starting work, everything will be ready.
• Training has been completed.
• The draft BUA letter was shown.
• Jeanot Muster made a motion to approve the draft BUA for Dr. Zalatan. A second is not needed since he is the Primary Reviewer.
• The Committee voted unanimously to approve the draft BUA for Dr. Zalatan with the understanding that the lab will be fully set up before any work commences.

FOR YOUR INFORMATION:
• Jacqui Bales presented information about BSL 2-with-3 practices.
She reminded the committee that BSL 2-with-3 practices is not an official containment level, but many institutions (including UW) use it.

One common misconception about BSL 2w/3 practices is that it includes mandatory respiratory protection. Respiratory protection is always determined by a risk assessment and is often recommended for BSL-3 agents.

The main differences between BSL-2 and BSL 2-with-3 practices include:

- Use of a rear-closing gown
- Decreasing the usage of sharps & glass whenever possible
- An available gowning and degowning area
- Site-specific training
- Site-specific BSL 2 w/3 practices manual

EH&S has a guidance document about BSL 3 practices. The IBC requested that this information be made available on the IBC website.

National Biosafety Stewardship Month is taking place in September. This notice was issued by the NIH in response to recent lapses in biosafety practices at federal laboratories. During National Biosafety Stewardship Month, UW has reached out to PIs/Lab Managers and research department administrators. They are encouraged to conduct inventories of infectious agents and toxins, ensuring that all agents are properly registered with the IBC. Labs are also encouraged to evaluate training and laboratory procedures that impact safety. EH&S and the IBC are engaging and reviewing internal programs and practices as well.

Post-Meeting Update: Please see http://www.ehs.washington.edu/rbsbiosafe/steward.shtm for more information.

MEETING ADJOURNED AT APPROXIMATELY 11:57.